ImpediMed (IPD) Q3 2025 TU earnings summary

Executive summary

• Achieved record Q3 FY25 revenue of $3.4 million, up 28% year-on-year and 2% sequentially, with record cash receipts of $4.1 million and a cash balance of $27.9 million, funding over eight quarters of operations.

• U.S. SOZO unit sales increased 10% sequentially, surpassing last year's total with a quarter remaining, while rest-of-world sales declined due to prior distributor restocking.

• Annual Recurring Revenue (ARR) reached $13.7 million, up 27% year-on-year and 10% sequentially.

• Strategic focus remains on breakeven through sales execution in BCRL, cost control, and expanding into new markets such as oncology and heart failure.

• Appointment of Scott Long as SVP of Sales, bringing over 30 years of experience, and recruitment of additional key account executives to accelerate sales conversion.

Financial highlights

• Record quarterly cash receipts of $4.1 million; operating cash outflow at $3.5 million, in line with forecast.

• Cash and cash equivalents at quarter end were $27.9 million, supporting 8.1 quarters of operating cash flow.

• Total Contracted Value (TCV) for the quarter was $4.9 million, with contract renewals averaging a 19% price increase.

• 36 SOZO units sold in Q3 FY25 (22 in US, up 10% sequentially), down from 49 units in Q2 FY25 due to lower rest-of-world sales.

• Churn rate remained low at under 3% per annum.

Outlook and guidance

• Forecasting a significant increase in U.S. SOZO sales in Q4 and the remainder of 2025, driven by a record pipeline of over 500 new leads.

• Continued investment in sales team, lead generation, and cost control, with focus on expanding executive leadership.

• Initiatives underway to broaden private payer coverage and expand into new clinical applications.

• Forecasts a one-off $1.2 million payment in Q4 FY25 to secure key electronic components at pre-tariff pricing.